ICC panel rules in flu drug dispute

North Carolina-based Biocryst Pharmaceuticals has reported a favourable ICC award terminating its agreement with an Australian-owned company for licensing of the world’s first intravenous flu treatment.


Get unlimited access to all Global Arbitration Review content